Ekso Bionics (EKSO) investor relations material

Company overview and business model

• Operates through two subsidiaries: Applied Digital Cloud Corporation (cloud services for AI/ML developers) and Ekso Bionics, Inc. (exoskeletons for healthcare), with plans to divest the exoskeleton business and focus solely on cloud services by Q1 2027.

• Cloud business provides energized colocation space and equipment for AI/ML workloads, with revenue currently concentrated in a single customer, Together AI.

• Recent business combination and holding company restructuring resulted in a new parent entity, with all shareholders maintaining their ownership percentage.

Financial performance and metrics

• Cloud business reported net losses of $72.7M for FY ended May 31, 2025, and $32.8M for the nine months ended Feb 28, 2026.

• Legacy Ekso business reported net losses of $11.7M for FY ended Dec 31, 2025, and $6.9M for the three months ended Mar 31, 2026.

• Issued 700,000 shares for $4.6M in warrant exercises in May 2026; 355,961 shares issued upon Series B Preferred Stock conversion.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling stockholders; company will only pay registration-related fees and expenses.

• Net proceeds from recent private placements were $3.2M (Oct 2025) and $5.3M (Jan 2026), used for general corporate purposes.